<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968433</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 38417</org_study_id>
    <nct_id>NCT02968433</nct_id>
  </id_info>
  <brief_title>The Stanford Parkinson's Disease Plasma Study</brief_title>
  <acronym>SPDP</acronym>
  <official_title>The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that young plasma infusions can be performed
      safely in patients with Parkinson's Disease (PD). Secondary outcomes will include behavioral
      and laboratory data that will support the next study that will inquire whether young plasma
      infusions improve or slow the progression of cognitive, mood and/or motor impairment and rate
      markers of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is a neurodegenerative disease that affects over 1.6 million people
      in the United States and whose incidence increases with age, affecting over 1% of people over
      the age of 65. The neuropathological processes involved in PD are widespread throughout the
      brain, and are reflected in a constellation of motor, cognitive, mood and other non-motor
      symptoms. Treatments to date have largely focused on dopamine replacement strategies or deep
      brain stimulation, both symptomatic treatments.

      As neurodegenerative diseases progress, there are major changes throughout the body and
      brain. These changes are transmitted in the body via the circulatory system between organs,
      tissues and cells. Recent findings from multiple laboratories have shown that infusions of
      young plasma into aging rodents can have beneficial effects on cognitive functions. This
      suggests that the circulating components of plasma can improve cognitive and disease-relevant
      symptoms. This has motivated the field to treat multiple disorders with blood products and
      their constituent active components.

      The established safety of blood transfusions allows the investigators to test whether
      infusions of young plasma can ease the neurological symptoms in human subjects with
      neurodegenerative diseases. A study that is ongoing at Stanford, in the department of
      Neurology and Neurological Sciences, is testing whether infusions of young plasma can
      ameliorate the cognitive impairment in patients with Alzheimer's disease (ClinicalTrials.gov
      identifier NCT02256306). To date, this has been well-tolerated by the participants, without
      major adverse effects.

      The investigator proposes to test the safety and efficacy of transfusing young plasma into PD
      participants, in order to establish its effects on motor and cognitive functions in
      participants in a Phase 1 study. The successful completion of this study will inform the
      design of future, larger and multicenter studies with the goal to determine whether infusions
      of young plasma can ameliorate the neurodegenerative symptoms and underlying pathophysiology
      in Parkinson's disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assesses by CTCAE v4.0</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary outcome measure is the number of participants with any adverse effects that might be related to young plasma infusions as a novel treatment to Parkinson's Disease symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline of quantitative data of motor movements</measure>
    <time_frame>1 weeks</time_frame>
    <description>The second outcome measure is the quantitative data of current motor movement ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quantitative data of motor movements from baseline</measure>
    <time_frame>7 weeks</time_frame>
    <description>The second outcome measure is the change in the quantitative data of current motor movement ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quantitative data of motor movements up to 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>The second outcome measure is the change in the quantitative data of current motor movement ability.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Baseline of quantitative data of cognitive ability</measure>
    <time_frame>2 weeks</time_frame>
    <description>The third outcome measure is quantitative data of current cognitive ability.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in quantitative data of cognitive ability</measure>
    <time_frame>7 weeks</time_frame>
    <description>The third outcome measure is the change in quantitative data of current cognitive ability.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Parkinson Disease(PD)</condition>
  <arm_group>
    <arm_group_label>Infusions of Young Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will undergo neuropsychological, neuropsychiatric, and kinematic assessments prior to receiving infusions of young plasma as the treatment.
Participants will receive 1 unit of young plasma, twice a week over a four week duration.
After the four weeks of plasma infusions, participants will undergo neuropsychological, neuropsychiatric and kinematic reassessments. No deception will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infusions of young plasma</intervention_name>
    <description>Participants will receive four weekly infusions of 1 unit young plasma (male, ages between 18-25)</description>
    <arm_group_label>Infusions of Young Plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of clinically probable or established Parkinson's Disease (MDS criteria)

          -  Subject must be on a stable dose of dopaminergic medication and/or Deep Brain
             Stimulation (DBS) parameters for at least 4 weeks prior to screening and for the
             duration of the study

          -  Subject must be competent to sign consent

          -  Subject must be willing to commit to being available for weekly infusions and testing
             for 4 consecutive weeks (or 8 weeks if the subject agrees to the longer study).

          -  The availability of a study partner who knows the patient well and is willing to
             accompany the subject to all trial

        Exclusion Criteria:

          -  The participation in any other interventional clinical trial

          -  The inability to travel to Stanford

          -  Inability to walk without assistance in the off or on medication state

          -  The clinically determined presence of dementia

          -  A clinical suspicion/diagnosis of Multiple System Atrophy (MSA), Progressive
             Supranuclear Palsy (PSP), Lewy Body Dementia (LBD), Essential Tremor (ET)

          -  Subject's pregnancy or likelihood of pregnancy within the next 6 months.

          -  Subject's positive test results for Hepatitis B, Hepatitis C or HIV at screening

          -  Any other condition or situation that the investigator believes may interfere with the
             safety of the subject or the intent and conduct of the study

          -  Subject's medical history of:

        Stroke Anaphylaxis Gout- may cause an increase in uric acid Prior adverse reaction to any
        human blood product Any history of a blood coagulation disorder or hypercoagulability
        Congestive heart failure Uncontrolled hypertension Renal failure Prior intolerance to
        intravenous fluids Recent history of uncontrolled atrial fibrillation immunoglobulin A
        deficiency (by history)

          -  Subject's relation to medications or other treatments:

          -  Any concurrent use of an anticoagulant therapy. Antiplatelet drugs (e.g., aspirin or
             clopidogrel) are acceptable.

          -  The use of Inosine, which may alter urate levels

          -  Initiation or change in the dosage of a cholinesterase inhibitor or memantine during
             the trial. A participant already on a cholinesterase inhibitor or memantine must be on
             a stable dose for at least one month prior to Screening.

          -  Concurrent participation in another interventional treatment trial for Parkinson's
             disease. If there was prior participation, the last dose of the investigational agent
             must have been at least 6 months prior to Screening.

          -  Treatment with any human blood product, including intravenous immunoglobulin, during
             the 6 months prior to Screening or during the trial.

          -  Concurrent daily treatment with benzodiazepines, typical or atypical antipsychotics,
             long-acting opioids, or other medications that, in the investigator's opinion,
             interfere with cognition. Intermittent treatment with short-acting benzodiazepines or
             atypical antipsychotics may be permitted, provided that no dose is administered within
             the 72 hours preceding any cognitive assessment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Bronte-Stewart, MS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Bronte-Stewart, MS, MD</last_name>
    <phone>(650) 723-2116</phone>
    <email>hbs@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Movement Disorders Clinic</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amaris Martinez, BA</last_name>
      <phone>650-723-6709</phone>
      <email>amaris94@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Despr√©s S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011 Aug 31;477(7362):90-4. doi: 10.1038/nature10357.</citation>
    <PMID>21886162</PMID>
  </reference>
  <reference>
    <citation>Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D, Wabl R, Udeochu J, Wheatley EG, Zou B, Simmons DA, Xie XS, Longo FM, Wyss-Coray T. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014 Jun;20(6):659-63. doi: 10.1038/nm.3569. Epub 2014 May 4.</citation>
    <PMID>24793238</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Helen M. Bronte-Stewart</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Young Male Plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

